Activist Investor & Director Kevin Tang's Group Boosts Stake to 9.2% with $12.7M Recent Purchases

summarizeSummary

Activist investor Tang Capital Management, led by Director Kevin Tang, has increased its stake in Aurinia Pharmaceuticals to 9.2% through recent open market purchases totaling $12.69 million, reinforcing confidence after strong earnings.

check_boxKey Events

• Activist Investor Group Increases Stake

  Tang Capital Management, LLC and its affiliates, including Director Kevin Tang, now beneficially own 12,229,500 common shares, representing 9.2% of Aurinia Pharmaceuticals Inc.'s outstanding shares.

• Significant Open Market Purchases

  The reporting persons acquired approximately $12.69 million worth of common shares through open market purchases in the past 60 days, with a total of $26.3 million spent on 2.2 million shares since March 4, 2025.

• Director's Conviction

  The continued accumulation by Kevin Tang, who is also a Director, signals strong insider confidence in the company's valuation and future performance, following the recent positive financial results.

auto_awesomeAnalysis

This Schedule 13D/A reveals that Tang Capital Management, LLC and its affiliates, including Director Kevin Tang, have significantly increased their beneficial ownership in Aurinia Pharmaceuticals to 9.2%. The group has made substantial open market purchases, totaling approximately $12.69 million in the past 60 days and $26.3 million since March 2025. This continued accumulation by an activist investor who also serves as a director signals strong conviction in the company's future prospects, especially following the recent positive financial results reported on February 26, 2026.